Klaus M. Kortum

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP
Published: May 13, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square
Published: April 17, 2026

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Journal: Haematologica
Published: September 30, 2025

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Journal: Haematologica
Published: September 23, 2025

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Journal: Haematologica
Published: September 11, 2025

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Journal: Leukemia
Published: August 15, 2025

TrkA abundance is increased in cutaneous nerves in bortezomib-induced neuropathy.

TrkA abundance is increased in cutaneous nerves in bortezomib-induced neuropathy.

Journal: Brain pathology (Zurich, Switzerland)
Published: July 20, 2025

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Journal: Clinical epigenetics
Published: July 03, 2025

Cardiovascular determinants of the 6-minute walk distance in cardiac transthyretin amyloidosis.

Cardiovascular determinants of the 6-minute walk distance in cardiac transthyretin amyloidosis.

Journal: BMC cardiovascular disorders
Published: June 12, 2025

Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan.

Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan.

Journal: Cancer medicine
Published: June 12, 2025

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Journal: Research square
Published: June 12, 2025

Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data.

Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data.

Journal: BMC cancer
Published: May 15, 2025
Showing 1-12 of 36

Last Updated: 09/26/2026